Neuphoria Therapeutics Inc. (NEUP)
↓ Download CSV- Sector Manufacturing
- Incorporated C3
- Fiscal year ends Jun 30
In fiscal 2025, Neuphoria Therapeutics Inc. reported revenue of $15.65M. The company ran a net loss, with a net margin of -2.4%. It held $28.59M in total assets against $9.59M in total liabilities.
Key ratios (FY2025)
-7.2%
Operating margin
-2.4%
Net margin
-1.9%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $15.65M | — | — | — |
| Operating Income | -$1.13M | -$17.89M | -$21.98M | — |
| Net Income | -$369.6K | -$15.49M | -$21.38M | — |
| EPS (Diluted) | $-0.23 | $-18.62 | $-0.02 | — |
| Total Assets | $28.59M | $27.65M | $28.56M | — |
| Total Liabilities | $9.59M | $10.16M | $6.55M | — |
| Shareholders' Equity | $19.00M | $17.49M | $22.01M | $39.23M |
| Cash & Equivalents | $14.21M | $12.61M | $12.10M | — |
| Operating Cash Flow | $77.2K | -$14.68M | -$14.64M | — |
| Shares Outstanding | 1.98M | 1.10M | 1.47B | — |